TickerTain — Make Analysis Fun Again

▶ 15:45 · $ATAI · Angermayer's main holding Atai brings psychedelic medicines to mainstream psychiatry

now playing · $ATAI

$ALNY···bullish· high· poschristian angermayer

Angermayer co-founded Alnylam on RNAi thesis, took public via SPAC at 25

RNAi technology could switch off genetic disease expression at the root cause, addressing a multi-billion dollar market with no existing treatments for genetic diseases.

$ATAI···bullish· high· poschristian angermayer

Angermayer's main holding Atai brings psychedelic medicines to mainstream psychiatry

Psychedelic compounds have near-zero downside when used medically with clinicians and can cure mental health issues; Atai is building the full suite of psychedelic medicines with…

$APEIRON-INVESTMENT-GROUPneutral· high· poschristian angermayer

Angermayer's family office Apeiron invests across lifecycle, seeds funds, and builds companies

Apeiron manages Angermayer's capital plus outside money, doing direct investments from seed to public equities, investing in third-party funds for diversification, and incubating…

$ENH···bullish· high· poschristian angermayer

Angermayer backs Enhanced Games: medical PEDs as recovery tools for athletes

FDA-approved performance-enhancing drugs under medical supervision help athletes recover from sport-induced bodily damage; Enhanced Games runs clinical trials to prove safety and…

$CMPS···bullish· high· poschristian angermayer

Angermayer seeded Compass Pathways, invested $1.5B proving psilocybin efficacy

Psilocybin can treat mental health with low doses; Compass proved the 1960s science works in modern trials, de-risking the entire psychedelic medicine category.

←